Cargando…

Desmopressin testing in von Willebrand disease: Lowering the burden

BACKGROUND: Individuals with von Willebrand disease (VWD) require desmopressin testing because of interindividual response differences. However, testing is burdensome, while not all patients may need extensive testing. OBJECTIVES: To provide von Willebrand factor (VWF) cutoffs that predict desmopres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heijdra, Jessica M., Atiq, Ferdows, Al Arashi, Wala, Kieboom, Quincy, Wuijster, Esmee, Meijer, Karina, Kruip, Marieke J. H. A., Leebeek, Frank W. G., Cnossen, Marjon H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512764/ https://www.ncbi.nlm.nih.gov/pubmed/36186107 http://dx.doi.org/10.1002/rth2.12784

Ejemplares similares

Criteria for low von Willebrand factor diagnosis and risk score to predict future bleeding
por: Atiq, Ferdows, et al.
Publicado: (2021)

Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study
por: Heijdra, Jessica M, et al.
Publicado: (2022)

Current and Emerging Options for the Management of Inherited von Willebrand Disease
por: Heijdra, Jessica M., et al.
Publicado: (2017)

Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2022)

Von Willebrand Factor Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease
por: Boender, Johan, et al.
Publicado: (2021)

How I manage severe von Willebrand disease
por: Leebeek, Frank W. G., et al.
Publicado: (2019)

Sports participation and physical activity in patients with von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2018)

Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age‐related increase of VWF in von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2018)

Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
por: Preijers, Tim, et al.
Publicado: (2020)

BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2019)

Social participation is reduced in type 3 Von Willebrand disease patients and in patients with a severe bleeding phenotype
por: Kempers, Eva K., et al.
Publicado: (2021)

Importance of Genotyping in von Willebrand Disease to Elucidate Pathogenic Mechanisms and Variability in Phenotype
por: Atiq, Ferdows, et al.
Publicado: (2022)

Platelet degranulation and bleeding phenotype in a large cohort of Von Willebrand disease patients
por: Swinkels, Maurice, et al.
Publicado: (2022)

ADAMTS‐13 and bleeding phenotype in von Willebrand disease
por: Boender, Johan, et al.
Publicado: (2020)

Desmopressin responsiveness by age in type 1 von Willebrand disease
por: Goldberg, Nicola, et al.
Publicado: (2020)

One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P(®)/Humate P(®) treatment in von Willebrand disease patients
por: de Jager, Nico C. B., et al.
Publicado: (2019)

Effect of Genetic Variation in STXBP5 and STX2 on von Willebrand Factor and Bleeding Phenotype in Type 1 von Willebrand Disease Patients
por: van Loon, Janine E., et al.
Publicado: (2012)

Quantitative 3D microscopy highlights altered von Willebrand factor α‐granule storage in patients with von Willebrand disease with distinct pathogenic mechanisms
por: Swinkels, Maurice, et al.
Publicado: (2021)

The one‐stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non‐severe haemophilia A: Superiority or non‐inferiority?
por: Schütte, Lisette M., et al.
Publicado: (2020)

Desmopressin as a Treatment in Patients With Von Willebrand Disease: A Systematic Review
por: Beltran, Andres, et al.
Publicado: (2023)

Von Willebrand disease type 2M: Correlation between genotype and phenotype
por: Maas, Dominique P. M. S. M., et al.
Publicado: (2021)

Desmopressin acetate use in von Willebrand’s disease: a survey on current practices in Brazil
por: Lopes, Maria Sueli da Silva Namen, et al.
Publicado: (2021)

Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study
por: van Galen, Karin P.M., et al.
Publicado: (2017)

Ex vivo Improvement of a von Willebrand Disease Type 2A Phenotype Using an Allele-Specific Small-Interfering RNA
por: de Jong, Annika, et al.
Publicado: (2020)

Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study
por: Schütte, Lisette M, et al.
Publicado: (2019)

Patient-relevant health outcomes for von Willebrand disease, platelet function disorders, and rare bleeding disorders: a Delphi study
por: van Hoorn, Evelien S., et al.
Publicado: (2023)

Desmopressin for bleeding in non‐severe hemophilia A: Suboptimal use in a real‐world setting
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022)

Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results
por: Leebeek, Frank W. G., et al.
Publicado: (2022)

New Developments in Diagnosis and Management of Acquired Hemophilia and Acquired von Willebrand Syndrome
por: Leebeek, Frank W. G.
Publicado: (2021)

von Willebrand Factor is elevated in HIV patients with a history of thrombosis
por: van den Dries, Lennert W. J., et al.
Publicado: (2015)

Hemophilia and von Willebrand disease: Factor VIII and von Willebrand factor
por: Sharma, Prashant
Publicado: (2019)

The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin
por: Kovacevic, Katarina D., et al.
Publicado: (2020)

Acquired von Willebrand Syndrome and Desmopressin Resistance During Venovenous Extracorporeal Membrane Oxygenation in Patients With COVID-19: A Prospective Observational Study
por: Kalbhenn, Johannes, et al.
Publicado: (2022)

Diagnostic Value of Measuring Platelet Von Willebrand Factor in Von Willebrand Disease
por: Casonato, Alessandra, et al.
Publicado: (2016)

Performance Related Factors Are the Main Determinants of the von Willebrand Factor Response to Exhaustive Physical Exercise
por: van Loon, Janine E., et al.
Publicado: (2014)

Changes of von Willebrand Factor during Pregnancy in Women with and without von Willebrand Disease
por: Castaman, Giancarlo
Publicado: (2013)

Genetic Variation in the von Willebrand Factor Gene in Swedish von Willebrand Disease Patients
por: Manderstedt, Eric, et al.
Publicado: (2018)

Patient‐reported outcomes in autosomal inherited bleeding disorders: A systematic literature review
por: van Hoorn, Evelien S., et al.
Publicado: (2022)

Desmopressin in moderate hemophilia A patients: a treatment worth considering
por: Loomans, Janneke I., et al.
Publicado: (2018)

Von Willebrand Disease: An Overview
por: Bharati, K. Pavani, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_fltv1oi1uc7e24sj84l6iv1g5m